Buy Jubilant Life Sciences, target Rs 1,040: Siddharth Sedani
on
Get link
Facebook
X
Pinterest
Email
Other Apps
With the planned IPO for its Singapore subsidiary, JLS will go onto further reduce its net debt while continuing additional capex, says Siddharth Sedani of Anand Rathi Shares and Stock Brokers.
With the planned IPO for its Singapore subsidiary, JLS will go onto further reduce its net debt while continuing additional capex, says Siddharth Sedani of Anand Rathi Shares and Stock Brokers.
Comments
Post a Comment